The setback comes at a crucial time for Novo Nordisk, which had positioned CagriSema as its next-generation weight-loss treatment. The current generation, made up of blockbuster drugs like Wegovy and Ozempic, have been cash cows for Novo.

Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, and stay competitive. Click for more.

Novo Nordisk shares declined on Monday after the company reported that its next-generation weight-loss drug, CagriSema, helped obese or overweight adult patients with type 2 diabetes reduce their weight by 15.7% after 68 weeks. The stock dropped around 6.5% in Copenhagen, marking its biggest intraday decline since December 20.